Sponsors (9)
The bill provides clearer, more predictable federal rules and private remedies around a specific abortion medication, but does so by restricting importation and increasing liability—likely reducing access to medication abortion, creating legal and operational burdens for providers and carriers, and limiting regulators' flexibility to update safety rules.
Hospitals, pharmacies, healthcare providers, and patients gain clearer, more predictable regulatory rules because the bill reverts REMS and clarifies statutory definitions, reducing short‑term administrative uncertainty for dispensing and monitoring the drug.
Pregnant people and patients using mifepristone are explicitly covered by the Act, which can help protect domestic legal access and clarify that the medication is addressed by federal law.
People who suffer physical or mental harm from certain abortion medications (and their attorneys) gain a federal cause of action allowing compensatory and punitive damages and recovery of attorney’s fees, with state‑law remedies remaining available.
Women and others seeking medication abortion will face substantially reduced access to mifepristone because the bill bans importation and restricts cross‑border/telehealth routes, increasing barriers to care and raising the risk some people will seek unsafe alternatives.
Telehealth providers, pharmacies, and clinics face increased federal civil liability for facilitating or distributing abortion medications, likely prompting many providers to stop offering services and thereby reducing telehealth access to medication.
Mandating or restoring an older, specific REMS (the June 2011 program) limits HHS flexibility to update safety monitoring and access rules, may not reflect current evidence or best practices, and can hinder responses to new safety signals or public‑health emergencies.
Based on analysis of 5 sections of legislative text.
Reinstates the 2011 REMS for mifepristone, bans its importation (including by mail), and creates a federal civil cause of action against telehealth providers, pharmacies, and importers for harms tied to the drug.
Requires the Department of Health and Human Services to reinstate the 2011 REMS (risk evaluation and mitigation strategy) for mifepristone within 90 days, bans the importation of mifepristone into the United States (including by mail), and creates a federal civil cause of action allowing people harmed by certain abortion medications to sue telehealth providers, pharmacies, and importers/transporters for damages. The civil suit provision permits compensatory and punitive damages plus attorneys’ fees and preserves state-law remedies.
Introduced September 30, 2025 by Mary E. Miller · Last progress September 30, 2025